We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer
Read MoreHide Full Article
AstraZenecaPLC (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the European Commission has approved their PARP inhibitor Lynparza for the treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Following this development, Lynparza becomes the first PARP inhibitor to get the nod for treating biomarker-selected patients with advanced pancreatic cancer.
The approval in the EU was based on positive data from the phase III POLO study, which evaluated Lynparza as maintenance monotherapy versus placebo. Data from the study showed that treatment with Lynparza nearly doubled median progression-free survival after first-line chemotherapy in the given patient population as compared to placebo.
Per the company, treatment with Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months as compared to 3.8 months on placebo. This safety and tolerability profile of Lynparza in the study was similar to previous studies.
Last December, Lynparza was approved by the FDA for a similar indication in the United States. The drug is already approved for multiple indications in advanced ovarian cancer and metastatic breast cancer.
Shares of AstraZeneca have increased 7.2% in the year so far against the industry’s decrease of 1.2%.
Lynparza, presently approved for three tumor types including ovarian, breast and pancreatic, was given the nod for metastatic castration-resistant prostate cancer (with HRR genetic mutations) in May 2020, which marked the drug’s approval for the fourth cancer type. Lynparza is also being evaluated in combination with Merck’s Keytruda for NSCLC.
Notably, AstraZeneca also has a profit- sharing deal with Merck for Lynparza.
In the first quarter of 2020, Lynparza sales rose 69% year over year to $397 million on the back of an expanded use in ovarian and breast cancer. Further label expansion of the drug will boost sales significantly in the future quarters. Lynparza achieved a blockbuster status in 2019.
Other FDA-approved PARP inhibitors include Clovis Oncology’s Rubraca, Glaxo’s (GSK - Free Report) Zejula and Pfizer’s (PFE - Free Report) Talzenna. Lynparza enjoys advantage in the PARP inhibitor segment as it is approved for most oncology indications.
In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.
Image: Bigstock
AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer
AstraZeneca PLC (AZN - Free Report) and partner Merck (MRK - Free Report) announced that the European Commission has approved their PARP inhibitor Lynparza for the treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
Following this development, Lynparza becomes the first PARP inhibitor to get the nod for treating biomarker-selected patients with advanced pancreatic cancer.
The approval in the EU was based on positive data from the phase III POLO study, which evaluated Lynparza as maintenance monotherapy versus placebo. Data from the study showed that treatment with Lynparza nearly doubled median progression-free survival after first-line chemotherapy in the given patient population as compared to placebo.
Per the company, treatment with Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months as compared to 3.8 months on placebo. This safety and tolerability profile of Lynparza in the study was similar to previous studies.
Last December, Lynparza was approved by the FDA for a similar indication in the United States. The drug is already approved for multiple indications in advanced ovarian cancer and metastatic breast cancer.
Shares of AstraZeneca have increased 7.2% in the year so far against the industry’s decrease of 1.2%.
Lynparza, presently approved for three tumor types including ovarian, breast and pancreatic, was given the nod for metastatic castration-resistant prostate cancer (with HRR genetic mutations) in May 2020, which marked the drug’s approval for the fourth cancer type. Lynparza is also being evaluated in combination with Merck’s Keytruda for NSCLC.
Notably, AstraZeneca also has a profit- sharing deal with Merck for Lynparza.
In the first quarter of 2020, Lynparza sales rose 69% year over year to $397 million on the back of an expanded use in ovarian and breast cancer. Further label expansion of the drug will boost sales significantly in the future quarters. Lynparza achieved a blockbuster status in 2019.
Other FDA-approved PARP inhibitors include Clovis Oncology’s Rubraca, Glaxo’s (GSK - Free Report) Zejula and Pfizer’s (PFE - Free Report) Talzenna. Lynparza enjoys advantage in the PARP inhibitor segment as it is approved for most oncology indications.
Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks to Soar Past the Pandemic:
In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.
See the 5 high-tech stocks now>>